You are here: Industry Insights > Mylan

News List

Mylan, Theravance's Yupelri approved by FDA for COPD pharmafile
November 12, 2018
Mylan and Theravance Biopharma on Friday announced that the FDA approved Yupelri (revefenacin) as a maintenance treatment for patients with chronic obstructive
Mylan and Theravance’s COPD treatment gets FDA approval expressbpd
November 12, 2018
The treatment, Yupelri, is a once-daily inhalable solution to be used by patients of COPD
Mylan and Theravance’s COPD treatment gets FDA approval expressbpd
November 10, 2018
Theravance Biopharma and partner Mylan won US regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.
Perrigo rejects Mylan's acquisition bid biospectrumasia
October 12, 2018
Perrigo rejects Mylan's acquisition bid
Mylan, Fujifilm score EU thumbs-up for Humira biosimilar, putting more pressure on AbbVie fiercepharma
September 21, 2018
AbbVie and its investors have been fretting over the potential impact of biosimilar competition to Humira—the world’s top-selling drug, with more than $18 billion a year in sales—and now they have another contender to worry about.
Mylan biosimilar to stress test Amgen Neulasta franchise, analyst predicts biopharmadive
September 20, 2018
The importance of Mylan's copycat extends well beyond the bottom lines of the two drugmakers directly involved. Leerink analyst Geoffrey Porges called it "the latest battle" in the space that "will set the industry tone for biosimilar adoption in the near
Mylan Launches Generic Brevibloc Injection in Single-Dose Bags americanpharmaceuticalreview
September 14, 2018
Mylan announced the U.S. launch of Esmolol Hydrochloride in Sodium Chloride Injection, 2,500 mg/250 mL (10 mg/mL) Single-Dose Plastic Bag and 2,000 mg/100 mL (20 mg/mL) Single-Dose Plastic Bag, the first generic version of Brevibloc.
Analyst chastises Mylan—not known for its transparency—for under-the-radar dealmaking fiercepharma
August 17, 2018
Mylan unveiled plenty of news in its second-quarter earnings release last week, including that its revenues were down year over year and that it was lowering guidance. But there was also some key info it didn’t include.
Mylan brings first generic for Adcirca tablets biospectrumasia
August 15, 2018
Tadalafil is indicated in the treatment of pulmonary arterial hypertension to improve exercise ability
Can a strategic review solve Mylan's problems? Don't count on it fiercepharma
August 10, 2018
Mylan needs some serious help, and it's looking at its options—like selling off assets, or even the whole company—to keep shareholders happy. But it may not have that many options.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page